Chinese General Practice ›› 2025, Vol. 28 ›› Issue (08): 962-972.DOI: 10.12114/j.issn.1007-9572.2023.0768
• Original Research • Previous Articles
Received:
2023-10-10
Revised:
2024-03-30
Published:
2025-03-15
Online:
2025-01-02
Contact:
HE Junqin
通讯作者:
何军琴
作者简介:
作者贡献:
李梦元负责提出研究思路,设计研究方案及论文起草;李冠杉负责实验;韩倩、李思瑶及郑舒畅负责数据的收集与整理;辛明蔚、王景尚、武颖负责绘图与展示;尹晓丹进行论文修订;何军琴负责最终版本修订,对论文负责。
基金资助:
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0768
组别 | 例数 | 细胞增殖 | 细胞迁移 | ||||||
---|---|---|---|---|---|---|---|---|---|
第0天 | 第1天 | 第2天 | 第3天 | 第4天 | 24 h | 48 h | 72 h | ||
正常对照组 | 12 | 26.33±0.15 | 43.17±0.70 | 81.07±0.51 | 92.87±1.53 | 126.83±3.68 | 18.48±0.26 | 47.10±0.51 | 85.78±2.80 |
RSA组 | 12 | 26.57±0.55 | 42.07±0.25 | 70.77±0.51 | 81.27±1.50 | 92.00±2.55 | 16.34±0.34 | 37.07±0.45 | 71.70±1.31 |
t值 | 0.707 | 2.554 | 24.580 | 9.381 | 13.460 | 8.571 | 25.550 | 7.885 | |
P值 | 0.518 | 0.063 | <0.001 | <0.001 | <0.001 | 0.001 | <0.001 | <0.001 | |
组别 | 细胞侵袭 | CD44+/CD24+ | EMT标志蛋白 | 黏附蛋白 | |||||
E-cadherin | N-cadherin | Vimentin | MMP-7 | MMP-9 | |||||
正常对照组 | 63.10±2.74 | 29.62±1.06 | 1.01±0.08 | 2.74±0.15 | 2.14±0.31 | 2.39±0.05 | 2.60±0.07 | ||
RSA组 | 39.03±2.63 | 13.11±1.65 | 1.89±0.05 | 2.16±0.15 | 0.79±0.12 | 1.78±0.14 | 2.12±0.07 | ||
t值 | 11.110 | 14.600 | 16.600 | 4.626 | 7.112 | 7.303 | 6.785 | ||
P值 | <0.001 | <0.001 | <0.001 | 0.010 | 0.002 | 0.002 | 0.002 |
Table 1 EMT assessments in endometrial epithelial cells of mice in the two groups
组别 | 例数 | 细胞增殖 | 细胞迁移 | ||||||
---|---|---|---|---|---|---|---|---|---|
第0天 | 第1天 | 第2天 | 第3天 | 第4天 | 24 h | 48 h | 72 h | ||
正常对照组 | 12 | 26.33±0.15 | 43.17±0.70 | 81.07±0.51 | 92.87±1.53 | 126.83±3.68 | 18.48±0.26 | 47.10±0.51 | 85.78±2.80 |
RSA组 | 12 | 26.57±0.55 | 42.07±0.25 | 70.77±0.51 | 81.27±1.50 | 92.00±2.55 | 16.34±0.34 | 37.07±0.45 | 71.70±1.31 |
t值 | 0.707 | 2.554 | 24.580 | 9.381 | 13.460 | 8.571 | 25.550 | 7.885 | |
P值 | 0.518 | 0.063 | <0.001 | <0.001 | <0.001 | 0.001 | <0.001 | <0.001 | |
组别 | 细胞侵袭 | CD44+/CD24+ | EMT标志蛋白 | 黏附蛋白 | |||||
E-cadherin | N-cadherin | Vimentin | MMP-7 | MMP-9 | |||||
正常对照组 | 63.10±2.74 | 29.62±1.06 | 1.01±0.08 | 2.74±0.15 | 2.14±0.31 | 2.39±0.05 | 2.60±0.07 | ||
RSA组 | 39.03±2.63 | 13.11±1.65 | 1.89±0.05 | 2.16±0.15 | 0.79±0.12 | 1.78±0.14 | 2.12±0.07 | ||
t值 | 11.110 | 14.600 | 16.600 | 4.626 | 7.112 | 7.303 | 6.785 | ||
P值 | <0.001 | <0.001 | <0.001 | 0.010 | 0.002 | 0.002 | 0.002 |
组别 | 例数 | 细胞增殖 | 细胞迁移 | ||||||
---|---|---|---|---|---|---|---|---|---|
第0天 | 第1天 | 第2天 | 第3天 | 第4天 | 24 h | 48 h | 72 h | ||
RSA | 12 | 27.27±0.21 | 42.57±0.64 | 70.47±1.42 | 80.97±1.42 | 95.57±1.58 | 17.15±0.05 | 35.11±6.56 | 54.85±0.55 |
RSA+Ex | 12 | 26.59±0.65 | 42.50±0.60 | 80.97±1.94 | 93.30±3.16 | 129.47±5.23 | 17.24±0.13 | 48.89±1.15 | 64.17±0.43 |
t值 | 0.707 | 0.132 | 7.560 | 6.171 | 10.740 | 1.103 | 3.583 | 23.600 | |
P值 | 1.721 | 0.901 | 0.002 | 0.004 | <0.001 | 0.332 | 0.023 | <0.001 | |
组别 | 细胞侵袭 | CD44+/CD24+ | EMT标志蛋白 | 黏附蛋白 | |||||
E-cadherin | N-cadherin | Vimentin | MMP-7 | MMP-9 | |||||
RSA | 26.27±1.91 | 11.82±1.53 | 3.47±0.47 | 2.44±0.15 | 2.32±0.25 | 1.92±0.15 | 1.69±0.10 | ||
RSA+Ex | 54.33±2.52 | 30.88±1.46 | 1.21±0.33 | 4.45±0.51 | 3.20±0.08 | 2.36±0.10 | 1.96±0.10 | ||
t值 | 15.380 | 15.610 | 16.600 | 6.535 | 5.855 | 4.133 | 3.432 | ||
P值 | <0.001 | <0.001 | <0.001 | 0.003 | 0.004 | 0.0145 | 0.026 |
Table 2 Impact of exosomes on EMT of mouse endometrial epithelial cells
组别 | 例数 | 细胞增殖 | 细胞迁移 | ||||||
---|---|---|---|---|---|---|---|---|---|
第0天 | 第1天 | 第2天 | 第3天 | 第4天 | 24 h | 48 h | 72 h | ||
RSA | 12 | 27.27±0.21 | 42.57±0.64 | 70.47±1.42 | 80.97±1.42 | 95.57±1.58 | 17.15±0.05 | 35.11±6.56 | 54.85±0.55 |
RSA+Ex | 12 | 26.59±0.65 | 42.50±0.60 | 80.97±1.94 | 93.30±3.16 | 129.47±5.23 | 17.24±0.13 | 48.89±1.15 | 64.17±0.43 |
t值 | 0.707 | 0.132 | 7.560 | 6.171 | 10.740 | 1.103 | 3.583 | 23.600 | |
P值 | 1.721 | 0.901 | 0.002 | 0.004 | <0.001 | 0.332 | 0.023 | <0.001 | |
组别 | 细胞侵袭 | CD44+/CD24+ | EMT标志蛋白 | 黏附蛋白 | |||||
E-cadherin | N-cadherin | Vimentin | MMP-7 | MMP-9 | |||||
RSA | 26.27±1.91 | 11.82±1.53 | 3.47±0.47 | 2.44±0.15 | 2.32±0.25 | 1.92±0.15 | 1.69±0.10 | ||
RSA+Ex | 54.33±2.52 | 30.88±1.46 | 1.21±0.33 | 4.45±0.51 | 3.20±0.08 | 2.36±0.10 | 1.96±0.10 | ||
t值 | 15.380 | 15.610 | 16.600 | 6.535 | 5.855 | 4.133 | 3.432 | ||
P值 | <0.001 | <0.001 | <0.001 | 0.003 | 0.004 | 0.0145 | 0.026 |
组别 | 例数 | miRNA-133a | miRNA-158-5P | miRNA-221 | miRNA-720 | miRNA-365 | miRNA-215 | miRNA-34a |
---|---|---|---|---|---|---|---|---|
正常对照组 | 12 | 0.92±0.06 | 0.93±0.07 | 5.07±0.10 | 0.92±0.06 | 0.92±0.05 | 0.97±0.12 | 0.92±0.06 |
RSA组 | 12 | 1.18±0.04 | 2.10±0.12 | 1.05±0.14 | 0.49±0.03 | 1.13±0.07 | 5.65±0.46 | 0.42±0.03 |
t值 | 6.390 | 14.000 | 40.550 | 11.970 | 4.209 | 17.190 | 13.690 | |
P值 | 0.003 | <0.001 | <0.001 | <0.001 | 0.014 | <0.001 | <0.001 |
Table 3 Expression levels of exosomal miRNAs between the two groups
组别 | 例数 | miRNA-133a | miRNA-158-5P | miRNA-221 | miRNA-720 | miRNA-365 | miRNA-215 | miRNA-34a |
---|---|---|---|---|---|---|---|---|
正常对照组 | 12 | 0.92±0.06 | 0.93±0.07 | 5.07±0.10 | 0.92±0.06 | 0.92±0.05 | 0.97±0.12 | 0.92±0.06 |
RSA组 | 12 | 1.18±0.04 | 2.10±0.12 | 1.05±0.14 | 0.49±0.03 | 1.13±0.07 | 5.65±0.46 | 0.42±0.03 |
t值 | 6.390 | 14.000 | 40.550 | 11.970 | 4.209 | 17.190 | 13.690 | |
P值 | 0.003 | <0.001 | <0.001 | <0.001 | 0.014 | <0.001 | <0.001 |
组别 | 例数 | 细胞增殖 | 细胞迁移 | 细胞侵袭 | CD44+/CD24+ | |||||
---|---|---|---|---|---|---|---|---|---|---|
第1天 | 第2天 | 第3天 | 第4天 | 24 h | 48 h | 72 h | ||||
Scrambled miR | 12 | 18.67±0.67 | 36.90±0.40 | 57.53±0.65 | 79.63±3.52 | 19.11±0.14 | 45.16±0.96 | 66.2±0.40 | 31.73±1.53 | 21.64±1.09 |
miR-221 mimic | 12 | 18.07±0.67 | 38.20±0.30 | 73.17±4.14 | 102.13±3.00 | 20.23±0.17 | 52.53±1.02 | 74.29±1.04 | 60.36±2.54 | 32.83±1.53 |
miR-221 inhibi | 12 | 18.07±0.38 | 37.23±0.25 | 40.93±1.72 | 70.73±8.11 | 17.22±0.15 | 36.06±0.22 | 58.50±0.87 | 25.51±3.90 | 11.82±1.53 |
F值 | 1.067 | 13.100 | 113.900 | 27.040 | 296.300 | 303.900 | 282.100 | 129.500 | 169.900 | |
P值 | 0.401 | 0.006 | <0.001 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 4 The impact of exosomal miRNA-221 on EMT
组别 | 例数 | 细胞增殖 | 细胞迁移 | 细胞侵袭 | CD44+/CD24+ | |||||
---|---|---|---|---|---|---|---|---|---|---|
第1天 | 第2天 | 第3天 | 第4天 | 24 h | 48 h | 72 h | ||||
Scrambled miR | 12 | 18.67±0.67 | 36.90±0.40 | 57.53±0.65 | 79.63±3.52 | 19.11±0.14 | 45.16±0.96 | 66.2±0.40 | 31.73±1.53 | 21.64±1.09 |
miR-221 mimic | 12 | 18.07±0.67 | 38.20±0.30 | 73.17±4.14 | 102.13±3.00 | 20.23±0.17 | 52.53±1.02 | 74.29±1.04 | 60.36±2.54 | 32.83±1.53 |
miR-221 inhibi | 12 | 18.07±0.38 | 37.23±0.25 | 40.93±1.72 | 70.73±8.11 | 17.22±0.15 | 36.06±0.22 | 58.50±0.87 | 25.51±3.90 | 11.82±1.53 |
F值 | 1.067 | 13.100 | 113.900 | 27.040 | 296.300 | 303.900 | 282.100 | 129.500 | 169.900 | |
P值 | 0.401 | 0.006 | <0.001 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | E-cadherin | N-cadherin | Vimentin | MMP-7 | MMP-9 | P-IKKα/β | IKKα/β |
---|---|---|---|---|---|---|---|---|
Scrambled miR | 12 | 0.85±0.04 | 0.63±0.05 | 0.69±0.06 | 1.04±0.08 | 0.74±0.04 | 1.73±0.15 | 1.02±0.06 |
miR-221 mimic | 12 | 0.67±0.05 | 1.06±0.06 | 0.93±0.06 | 1.20±0.03 | 1.71±0.17 | 4.13±0.08 | 1.01±0.06 |
miR-221 inhibi | 12 | 1.64±0.10 | 0.51±0.02 | 0.46±0.02 | 0.48±0.07 | 0.40±0.06 | 1.22±0.12 | 1.01±0.04 |
F值 | 127.700 | 114.100 | 65.790 | 104.000 | 121.400 | 61.820 | 0.042 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.958 | |
组别 | P-p38 | p38 | IL-6 | EGFR | P-Akt | Akt | Pten | |
Scrambled miR | 0.36±0.12 | 0.75±0.05 | 0.96±0.01 | 1.48±0.06 | 3.15±0.03 | 1.56±0.12 | 1.46±0.02 | |
miR-221 mimic | 1.77±0.12 | 0.81±0.04 | 0.92±0.03 | 1.46±0.06 | 2.40±0.25 | 1.45±0.31 | 1.38±0.17 | |
miR-221 inhibi | 1.43±0.10 | 0.80±0.05 | 0.93±0.01 | 1.45±0.05 | 2.56±0.27 | 1.62±0.21 | 3.54±0.21 | |
F值 | 131.100 | 1.314 | 2.603 | 0.531 | 10.270 | 0.411 | 177.100 | |
P值 | <0.001 | 0.336 | 0.154 | 0.613 | 0.011 | 0.680 | <0.001 |
Table 5 The impact of exosomal miRNA-221 on EMT
组别 | 例数 | E-cadherin | N-cadherin | Vimentin | MMP-7 | MMP-9 | P-IKKα/β | IKKα/β |
---|---|---|---|---|---|---|---|---|
Scrambled miR | 12 | 0.85±0.04 | 0.63±0.05 | 0.69±0.06 | 1.04±0.08 | 0.74±0.04 | 1.73±0.15 | 1.02±0.06 |
miR-221 mimic | 12 | 0.67±0.05 | 1.06±0.06 | 0.93±0.06 | 1.20±0.03 | 1.71±0.17 | 4.13±0.08 | 1.01±0.06 |
miR-221 inhibi | 12 | 1.64±0.10 | 0.51±0.02 | 0.46±0.02 | 0.48±0.07 | 0.40±0.06 | 1.22±0.12 | 1.01±0.04 |
F值 | 127.700 | 114.100 | 65.790 | 104.000 | 121.400 | 61.820 | 0.042 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.958 | |
组别 | P-p38 | p38 | IL-6 | EGFR | P-Akt | Akt | Pten | |
Scrambled miR | 0.36±0.12 | 0.75±0.05 | 0.96±0.01 | 1.48±0.06 | 3.15±0.03 | 1.56±0.12 | 1.46±0.02 | |
miR-221 mimic | 1.77±0.12 | 0.81±0.04 | 0.92±0.03 | 1.46±0.06 | 2.40±0.25 | 1.45±0.31 | 1.38±0.17 | |
miR-221 inhibi | 1.43±0.10 | 0.80±0.05 | 0.93±0.01 | 1.45±0.05 | 2.56±0.27 | 1.62±0.21 | 3.54±0.21 | |
F值 | 131.100 | 1.314 | 2.603 | 0.531 | 10.270 | 0.411 | 177.100 | |
P值 | <0.001 | 0.336 | 0.154 | 0.613 | 0.011 | 0.680 | <0.001 |
组别 | 例数 | P-Akt | Akt | Pten |
---|---|---|---|---|
Control | 12 | 1.76±0.08 | 1.38±0.15 | 2.54±0.12 |
SF1670 | 12 | 2.49±0.08 | 1.35±0.13 | 1.35±0.05 |
PF-04691502 | 12 | 3.53±0.17 | 1.40±0.04 | 1.56±0.17 |
F值 | 163.10 | 0.18 | 79.48 | |
P值 | <0.001 | 0.840 | <0.001 |
Table 6 The impact of the PI3K-AKT inhibitor on the PI3K-AKT signaling pathway
组别 | 例数 | P-Akt | Akt | Pten |
---|---|---|---|---|
Control | 12 | 1.76±0.08 | 1.38±0.15 | 2.54±0.12 |
SF1670 | 12 | 2.49±0.08 | 1.35±0.13 | 1.35±0.05 |
PF-04691502 | 12 | 3.53±0.17 | 1.40±0.04 | 1.56±0.17 |
F值 | 163.10 | 0.18 | 79.48 | |
P值 | <0.001 | 0.840 | <0.001 |
组别 | 例数 | 细胞侵袭能力 | E-cadherin | N-cadherin | Vimentin | P-Akt | Akt |
---|---|---|---|---|---|---|---|
Control | 12 | 40.90±0.56 | 3.16±0.09 | 2.41±0.11 | 2.62±0.23 | 3.54±0.26 | 1.30±0.13 |
miR-221 mimic | 12 | 76.53±1.98 | 5.11±0.04 | 2.25±0.12 | 0.82±0.10 | 0.74±0.10 | 1.10±0.06 |
miR-221 mimic+PF-04691502 | 12 | 55.26±2.50 | 4.24±0.06 | 4.76±0.23 | 3.17±0.20 | 2.33±0.15 | 0.86±0.06 |
F值 | 276.20 | 364.90 | 229.00 | 129.80 | 179.30 | 18.92 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.003 |
Table 7 The impact of the PI3K-AKT inhibitor on the EMT
组别 | 例数 | 细胞侵袭能力 | E-cadherin | N-cadherin | Vimentin | P-Akt | Akt |
---|---|---|---|---|---|---|---|
Control | 12 | 40.90±0.56 | 3.16±0.09 | 2.41±0.11 | 2.62±0.23 | 3.54±0.26 | 1.30±0.13 |
miR-221 mimic | 12 | 76.53±1.98 | 5.11±0.04 | 2.25±0.12 | 0.82±0.10 | 0.74±0.10 | 1.10±0.06 |
miR-221 mimic+PF-04691502 | 12 | 55.26±2.50 | 4.24±0.06 | 4.76±0.23 | 3.17±0.20 | 2.33±0.15 | 0.86±0.06 |
F值 | 276.20 | 364.90 | 229.00 | 129.80 | 179.30 | 18.92 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.003 |
分类 | 组合1 | 组合2 | 组合3 | 组合4 | 组合5 | 组合6 | 组合7 | 组合8 | F值 | P值 |
---|---|---|---|---|---|---|---|---|---|---|
miR-221 mimic | + | - | - | + | - | - | - | - | ||
miR-221 inhibi | - | + | - | - | + | - | - | - | ||
Scrambled miR | - | - | + | - | - | + | - | - | ||
Pten 3' UTR-WT | + | + | + | - | - | - | + | - | ||
Pten 3' UTR-Mut | - | - | - | + | + | + | - | + | ||
数值 | 4.28±0.12a | 26.11±0.21a | 14.75±0.53 | 13.53±0.07 | 13.14±0.40 | 13.64±0.46 | 13.53±0.31 | 13.52±0.07 | 1 024 | <0.001 |
Table 8 The regulatory role of miRNA-221 mimic on PTEN validated by dual luciferase reporter assay
分类 | 组合1 | 组合2 | 组合3 | 组合4 | 组合5 | 组合6 | 组合7 | 组合8 | F值 | P值 |
---|---|---|---|---|---|---|---|---|---|---|
miR-221 mimic | + | - | - | + | - | - | - | - | ||
miR-221 inhibi | - | + | - | - | + | - | - | - | ||
Scrambled miR | - | - | + | - | - | + | - | - | ||
Pten 3' UTR-WT | + | + | + | - | - | - | + | - | ||
Pten 3' UTR-Mut | - | - | - | + | + | + | - | + | ||
数值 | 4.28±0.12a | 26.11±0.21a | 14.75±0.53 | 13.53±0.07 | 13.14±0.40 | 13.64±0.46 | 13.53±0.31 | 13.52±0.07 | 1 024 | <0.001 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
武颖,张莹. 养血安胎方通过RAGE通路调控EMT治疗复发性流产的作用机制[J]. 中华中医药杂志,2021,36(4):2354-2358.
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[1] | LIU Taotao, LI Tianrong, WANG Xue, CHEN Jiameng, SHUAI Zhiqin, LI Lisheng, XU Shangfu. Nanoparticle- and Exosome-based Targeted Drug Delivery Systems Used in the Diagnosis and Treatment of Atherosclerosis: Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(08): 903-910. |
[2] | ZHANG Qinghua,PAN Jing,YAO Liyan. Etiological Factors of Recurrent Spontaneous Abortion [J]. Chinese General Practice, 2020, 23(14): 1760-1764. |
[3] | FENG Xiaoling,CHANG Zhuo,ZHAO Xiaoxuan,WANG Wei,LI Wenwen,CHEN Lu. Prevalence of Type D Personality and Distribution of TCM Syndromes in Unexplained Recurrent Spontaneous Abortion Patients [J]. Chinese General Practice, 2018, 21(34): 4227-4231. |
[4] | HE Ji-gang,LI Bei-bei,HAN Jin-xiu,LI Hong-rong,SA Ya-lian,YAN Dan,YANG Xiao-hua. GATA-4 Overexpressed Mouse Bone Marrow Mesenchymal Stem Cells Increase Anti-apoptosis by Secreting Exosome [J]. Chinese General Practice, 2018, 21(24): 2961-2966. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||